The Role of the cGAS-STING Signaling Pathway in the Immune Microenvironment of Gynecologic Malignancies and Therapeutic Application

doi:10.12280/gjfckx.20260130

Abstract

Abstract:

The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon gene (STING) signaling pathway is a central hub connecting cytosolic DNA sensing to antitumor immune activation and plays a significant role in remodeling the immune microenvironment of gynecologic malignancies. The mechanisms of activation and biological effects of this pathway differ among ovarian cancer, cervical cancer, and endometrial cancer. It can enhance antigen presentation, promote T-cell recruitment, and activate antitumor immunity. But it may also induce immunosuppression. Its regulation involves BRCA/DNA polymerase epsilon (POLE)-related alterations, interference by human papilloma virus (HPV) proteins, as well as microRNAs (miRNAs), epigenetic modifications, mitochondrial stress, and others. Research focusing on strategies such as STING agonists, poly (ADP-ribose) polymerase (PARP) inhibitors, immune checkpoint inhibitors, and nanodelivery systems shows promising application prospects. However, precise patient stratification, local delivery, dose control, and optimization of combination timing remain key challenges for clinical translation.

Key words: Genital neoplasms, female, Interferon typeⅠ, Tumor microenvironment, Antineoplastic combined chemotherapy protocols, cGAS-STING signaling pathway

WU Xue-li, ZHANG Xiu-xia, LIU Qian-qian, LIANG Xiao-lei, LIU Chang. The Role of the cGAS-STING Signaling Pathway in the Immune Microenvironment of Gynecologic Malignancies and Therapeutic Application[J]. Journal of International Obstetrics and Gynecology, 2026, 53(4): 367-373.

Figures/Tables 1

References 36

[1]	Vasiyani H, Wadhwa B, Singh R. Regulation of cGAS-STING signalling in cancer: Approach for combination therapy[J]. Biochim Biophys Acta Rev Cancer, 2023, 1878(3): 188896. doi: 10.1016/j.bbcan.2023.188896.
[2]	Zhang J, Yu S, Peng Q, et al. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies[J]. Cancer Biol Med, 2024, 21(1):45-64. doi: 10.20892/j.issn.2095-3941.2023.0440.
[3]	Li R, Liu H, Liu Y. The cGAS-STING pathway and female reproductive system diseases[J]. Front Immunol, 2024, 15:1447719. doi: 10.3389/fimmu.2024.1447719.
[4]	Pan X, Zhang W, Guo H, et al. Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists[J]. Biochem Pharmacol, 2023, 213:115596. doi: 10.1016/j.bcp.2023.115596.
[5]	Lu C, Wang W, Fu YX. Opportunities and challenges of targeting cGAS-STING in cancer[J]. Nat Rev Cancer, 2026, 26(3):200-216. doi: 10.1038/s41568-025-00894-9.
[6]	Yu L, Liu P. Cytosolic DNA sensing by cGAS: regulation, function, and human diseases[J]. Signal Transduct Target Ther, 2021, 6(1):170. doi: 10.1038/s41392-021-00554-y.
[7]	Decout A, Katz JD, Venkatraman S, et al. The cGAS-STING pathway as a therapeutic target in inflammatory diseases[J]. Nat Rev Immunol, 2021, 21(9):548-569. doi: 10.1038/s41577-021-00524-z. pmid: 33833439
[8]	Yu X, Cai L, Yao J, et al. Agonists and Inhibitors of the cGAS-STING Pathway[J]. Molecules, 2024, 29(13):3121. doi: 10.3390/molecules29133121.
[9]	Skopelja-Gardner S, An J, Elkon KB. Role of the cGAS-STING pathway in systemic and organ-specific diseases[J]. Nat Rev Nephrol, 2022, 18(9):558-572. doi: 10.1038/s41581-022-00589-6. pmid: 35732833
[10]	Gao M, He Y, Tang H, et al. cGAS/STING: novel perspectives of the classic pathway[J]. Mol Biomed, 2020, 1(1):7. doi: 10.1186/s43556-020-00006-z. pmid: 35006429
[11]	Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic[J]. Science, 2017, 355(6330):1152-1158. doi: 10.1126/science.aam7344. pmid: 28302823
[12]	Gronauer R, Madersbacher L, Monfort-Lanzas P, et al. Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy[J]. Front Immunol, 2024, 15:1489235. doi: 10.3389/fimmu.2024.1489235.
[13]	Chowdhury SR, Parikh CN, Kaur AN, et al. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors[J]. Proc Natl Acad Sci U S A, 2025, 122(39):e2514948122. doi: 10.1073/pnas.2514948122.
[14]	Huang X, Huo L, Xiao B, et al. Activating STING/TBK1 suppresses tumor growth via degrading HPV16/18 E7 oncoproteins in cervical cancer[J]. Cell Death Differ, 2024, 31(1):78-89. doi: 10.1038/s41418-023-01242-w. pmid: 38007552
[15]	Shah M, Anwar MA, Park S, et al. In silico mechanistic analysis of IRF3 inactivation and high-risk HPV E6 species-dependent drug response[J]. Sci Rep, 2015, 5:13446. doi: 10.1038/srep13446. pmid: 26289783
[16]	Zhu Q, Yu S. The role of cGAS-STING signaling in HPV infection and HPV-related cancers[J]. Front Immunol, 2025, 16:1709613. doi: 10.3389/fimmu.2025.1709613.
[17]	Lubbers JM, Koopman B, de Klerk-Sluis JM, et al. Association of homozygous variants of STING1 with outcome in human cervical cancer[J]. Cancer Sci, 2021, 112(1):61-71. doi: 10.1111/cas.14680.
[18]	Cai H, Yan L, Liu N, et al. IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway[J]. Biomed Pharmacother, 2020, 123:109790. doi: 10.1016/j.biopha.2019.109790. pmid: 31896065
[19]	Ouyang S, Xiong K, Chen P, et al. Mechanism of interaction between ANXA6 and cGAS to regulate STING signaling pathway and promote ferroptosis in cervical cancer[J]. Cancer Cell Int, 2025, 25(1):397. doi: 10.1186/s12935-025-03976-8.
[20]	Jiang H, Liu L, He S, et al. Dimethyl fumarate reprograms cervical cancer cells to enhance antitumor immunity by activating mtDNA-cGAS-STING pathway[J]. J Biomed Sci, 2025, 32(1):92. doi: 10.1186/s12929-025-01187-x.
[21]	Zeng X, Li X, Zhang Y, et al. IL6 Induces mtDNA Leakage to Affect the Immune Escape of Endometrial Carcinoma via cGAS-STING[J]. J Immunol Res, 2022, 2022:3815853. doi: 10.1155/2022/3815853.
[22]	Tang M, Yin S, Zeng H, et al. The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway[J]. Cell Death Dis, 2024, 15(1):69. doi: 10.1038/s41419-023-06418-3. pmid: 38238314
[23]	Li C, Zhu D, Cao X, et al. Knockdown of S100A2 inhibits the aggressiveness of endometrial cancer by activating STING pathway[J]. J Obstet Gynaecol, 2024, 44(1):2361849. doi: 10.1080/01443615.2024.2361849.
[24]	Chen G, Yan Q, Liu L, et al. Histone Deacetylase 3 Governs β-Estradiol-ERα-Involved Endometrial Tumorigenesis via Inhibition of STING Transcription[J]. Cancers(Basel), 2022, 14(19):4718. doi: 10.3390/cancers14194718.
[25]	Wu MZ, Cheng WC, Chen SF, et al. miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS[J]. Nat Cell Biol, 2017, 19(10):1286-1296. doi: 10.1038/ncb3615.
[26]	Bustos MA, Yokoe T, Shoji Y, et al. MiR-181a targets STING to drive PARP inhibitor resistance in BRCA-mutated triple-negative breast cancer and ovarian cancer[J]. Cell Biosci, 2023, 13(1):200. doi: 10.1186/s13578-023-01151-y.
[27]	Huang S, Li R, Huang X, et al. Association Study Between Methylation in the Promoter Regions of cGAS, MAVS, and TRAF3 Genes and the Risk of Cervical Precancerous Lesions and Cervical Cancer in a Southern Chinese Population[J]. Front Genet, 2019, 10:1123. doi: 10.3389/fgene.2019.01123. pmid: 31803230
[28]	Fan X, Song X, Chen W, et al. cGAS-STING signaling in cancer: Regulation and therapeutic targeting[J]. MedComm Oncol, 2023, 2(3):e49. doi: 10.1002/mog2.49.
[29]	Wang R, Hussain A, Guo Q, et al. cGAS-STING at the crossroads in cancer therapy[J]. Crit Rev Oncol Hematol, 2024, 193:104194. doi: 10.1016/j.critrevonc.2023.104194.
[30]	Lv QM, Lei HM, Wang SY, et al. Cancer cell-autonomous cGAS-STING response confers drug resistance[J]. Cell Chem Biol, 2023, 30(6):591-605.e4. doi: 10.1016/j.chembiol.2023.05.005.
[31]	Kristeleit R, Leary A, Oaknin A, et al. PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers[J]. Br J Cancer, 2024, 131(5):820-831. doi: 10.1038/s41416-024-02776-7.
[32]	Lampert EJ, Cimino-Mathews A, Lee JS, et al. Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses[J]. J Immunother Cancer, 2020, 8(2):e000516. doi: 10.1136/jitc-2019-000516.
[33]	de Queiroz N, Xia T, Konno H, et al. Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis[J]. Mol Cancer Res, 2019, 17(4):974-986. doi: 10.1158/1541-7786.MCR-18-0504. pmid: 30587523
[34]	Fu H, Liu X, Fang F, et al. Amplification of cGAS-STING pathway with "single-molecule multitarget" nanoparticles for chemo-immunotherapy of ovarian cancer[J]. Biomaterials, 2025, 323:123434. doi: 10.1016/j.biomaterials.2025.123434.
[35]	Fahey CG, Cordova AF, Gedeon PC, et al. Targeting STING to generate therapeutic anti-tumor immunity[J]. Cancer Cell, 2026, 44(2):260-280. doi: 10.1016/j.ccell.2025.12.002.
[36]	Zhang D, Zhang B. cGAS/STING signaling pathway in gynecological malignancies: From molecular mechanisms to therapeutic values[J]. Front Immunol, 2025, 16:1525736. doi: 10.3389/fimmu.2025.1525736.

药物名称	药物类型	适应证	组合/给药方式	临床试验分期	临床试验编号	状态	研究结果
MIW815（ADU- S100）	STING激动剂	晚期/转移性实体肿瘤或淋巴瘤	单药（肿瘤内注射）	Ⅰ期	NCT02675439	未提交注册平台结果	论文报告ORR为2.1%
MIW815（ADU- S100）	STING激动剂	晚期/转移性实体肿瘤或淋巴瘤	与PD-1检查点抑制剂 PDR001联合	Ⅰb期	NCT03172936	未提交注册平台结果	论文报告ORR为10.4%
MIW815（ADU- S100）	STING激动剂	复发/转移性头颈癌	与Pembrolizumab （Keytruda^®）联合	Ⅱ期	NCT03937141	已终止	官方记录16例入组，6例纳入ORR分析，其中1例CR、5例PR
MK-1454（Ulevostinag）	STING激动剂	晚期/转移性实体瘤或淋巴瘤	单药/与Pembrolizumab 联合	Ⅰ期	NCT03010176	完成	单药ORR为0%，联合ORR为24%（2018年阶段性结果）
E-7766	大环桥联型 STING激动剂	晚期实体瘤或淋巴瘤	肿瘤内注射	Ⅰ期	NCT04144140	已终止（非安全性原因）	ORR为0%；DCR为33.3%（8/24例SD）；常见治疗相关不良事件为寒战、发热和疲劳；3/23例在第1周期出现DLT
HG-381	非环二核苷酸类STING激动剂	晚期实体瘤	静脉给药	Ⅰ期	NCT04998422	招募中	尚无结果公布
GSK3745417	非环二核苷酸类STING激动剂	晚期实体瘤	静脉给药	Ⅰ期	NCT03843359	已终止（商业决策）	单药Q1W队列中2/24例出现DLT，Q3W队列中未出现DLT（0/7例）；与Dostarlimab联合时，GSK3745417采用Q1W（0/8例）或Q3W队列（0/13例）均未出现DLT；尚未报告ORR

药物名称	药物类型	适应证	组合/给药方式	临床试验分期	临床试验编号	状态	研究结果
MIW815（ADU- S100）	STING激动剂	晚期/转移性实体肿瘤或淋巴瘤	单药（肿瘤内注射）	Ⅰ期	NCT02675439	未提交注册平台结果	论文报告ORR为2.1%
MIW815（ADU- S100）	STING激动剂	晚期/转移性实体肿瘤或淋巴瘤	与PD-1检查点抑制剂 PDR001联合	Ⅰb期	NCT03172936	未提交注册平台结果	论文报告ORR为10.4%
MIW815（ADU- S100）	STING激动剂	复发/转移性头颈癌	与Pembrolizumab （Keytruda^®）联合	Ⅱ期	NCT03937141	已终止	官方记录16例入组，6例纳入ORR分析，其中1例CR、5例PR
MK-1454（Ulevostinag）	STING激动剂	晚期/转移性实体瘤或淋巴瘤	单药/与Pembrolizumab 联合	Ⅰ期	NCT03010176	完成	单药ORR为0%，联合ORR为24%（2018年阶段性结果）
E-7766	大环桥联型 STING激动剂	晚期实体瘤或淋巴瘤	肿瘤内注射	Ⅰ期	NCT04144140	已终止（非安全性原因）	ORR为0%；DCR为33.3%（8/24例SD）；常见治疗相关不良事件为寒战、发热和疲劳；3/23例在第1周期出现DLT
HG-381	非环二核苷酸类STING激动剂	晚期实体瘤	静脉给药	Ⅰ期	NCT04998422	招募中	尚无结果公布
GSK3745417	非环二核苷酸类STING激动剂	晚期实体瘤	静脉给药	Ⅰ期	NCT03843359	已终止（商业决策）	单药Q1W队列中2/24例出现DLT，Q3W队列中未出现DLT（0/7例）；与Dostarlimab联合时，GSK3745417采用Q1W（0/8例）或Q3W队列（0/13例）均未出现DLT；尚未报告ORR